Harnessing the Power
of Selectivity in
Complement Therapeutics

Who We Are

Dianthus Therapeutics is advancing next generation complement therapeutics to deliver transformative medicines for patients with rare diseases. Our mission is to develop best-in-class, potent and selective antibodies of validated and emerging complement targets to transform the lives of people living with autoimmune diseases.

Our
Approach

We envision the full potential of complement therapeutics lies within the power of selectivity. Our antibodies are modified with half-life extension technology and uniquely equipped with a high selectivity for active complement proteins, resulting in the potential for effective therapeutics with reduced dose levels and frequency to improve the lives of patients.

Pipeline

We are designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies.

DISCOVERY PRECLINICAL PHASE I/II PHASE I/II PIVOTAL STUDIES PIVOTAL STUDIES
DNTH103 – ACTIVE C1s SELECTIVE ANTIBODY
DNTH200
DNTH300
Team

At Dianthus, we are a multidisciplinary team of biotech entrepreneurs and scientists united by the commitment to harness the power of selectivity in complement therapeutics to create transformative medicines for people living with rare autoimmune diseases.

Team

At Dianthus, we are a multidisciplinary team of biotech entrepreneurs and scientists united by the commitment to harness the power of selectivity in complement therapeutics to create transformative medicines for people living with rare autoimmune diseases.

Leadership
  • Leadership
  • Board Of Directors
  • Investors
  • Leadership
  • Board Of Directors
  • Investors
Dianthus is supported by a strong syndicate of experienced life science investors, including 5AM Ventures, Avidity Partners, Fairmount, Fidelity Management & Research Company, Tellus BioVentures, Venrock, Wedbush Healthcare Partners, and others.
Join us

We believe in growth and persistence with change. With offices in Waltham, MA and New York City, NY, Dianthus is currently looking to strengthen our team with visionary, entrepreneurial scientists and experts motivated to make a lasting impact in the lives of patients through novel complement therapeutics. Grow with us.

View open positions

Current Job Openings

News
  • May 03 2022 | Dianthus Therapeutics Launches with $100M to Develop Selective Antibody Complement Therapeutics to Treat Severe and Rare Autoimmune Diseases
    Read More
    X
    News
    May 03 2022 | Dianthus Therapeutics Launches with $100M to Develop Selective Antibody Complement Therapeutics to Treat Severe and Rare Autoimmune Diseases

    Lead program DNTH103 to be accelerated to the clinic this year as a highly differentiated and potent monoclonal antibody designed to selectively target the active form of complement C1s

    Led by biotech veterans Marino Garcia as Chief Executive Officer and Lonnie Moulder as Chairman of the Board

    Financing co-led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company with strong investor syndicate

    Waltham, Mass. and New York City, May 3, 2022Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced the completion of its $100 million Series A financing led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company, with participation from additional investors including Wedbush Healthcare Partners and founding investors Fairmount, Tellus BioVentures, and Venrock Healthcare Capital Partners. The financing will be used to expand leadership and scientific teams, advance the company’s lead program, DNTH103, to the clinic this year, and to accelerate additional discovery pipeline programs for people living with severe and rare autoimmune diseases. DNTH103 is a potent, next-generation monoclonal antibody that selectively targets the active form of complement C1s, potentially enabling a lower dosing volume and a less frequent subcutaneous administration that is further enhanced with half-life extension technology.

    Dianthus also announced the appointment of Marino Garcia as President and Chief Executive Officer, joining in November 2021, and Simrat Randhawa, M.D., M.B.A., as Chief Medical Officer. Mr. Garcia, a veteran dealmaker and strategist, brings more than 25 years of industry experience in business development and operational leadership roles at top biotech and pharma companies, most recently as Senior Vice President, Corporate and Business Development at Zealand Pharma. Dr. Randhawa brings over 20 years of clinical practice and pharmaceutical industry experience to Dianthus, including senior leadership roles focused in the autoimmune and rare disease spaces. He most recently served as Senior Vice President of Clinical and Medical Affairs at Aurinia Pharmaceuticals.

    “We are committed to improving the lives of people living with severe and rare autoimmune diseases and are confident that our selective antibodies have the potential to be best-in-class therapeutics,” said Marino Garcia, President and Chief Executive Officer, Dianthus Therapeutics. “We are privileged to have a strong syndicate of leading biotech investors, experienced Board members, and accomplished leaders and scientists as we advance our lead candidate into the clinic later this year, further develop our discovery pipeline, and expand our team in the coming months. Dianthus is positioned to become a leading, next-generation complement company guided by a deep understanding of the needs of patients.”

    Dianthus harnesses the power of selectivity in complement pathways to create potent monoclonal antibodies with the potential to overcome the limitations of current complement therapeutics. Unlike current antibody therapies that bind to both inactive and active complement proteins, DNTH103 selectively targets only the active form of the C1s complement protein, enabling a lower dosing volume and less frequent administration. Its half-life extension technology also further reduces dosing frequency. With these differentiated attributes and high potency inhibition of C1s, DNTH103 is designed to relieve the burden of high-volume, frequent administration with IV infusions or inconvenient, frequent subcutaneous dosing. Accelerating the development of a more convenient subcutaneous therapy could be transformative in expanding the potential patient populations that could benefit from complement therapies, while reducing the discomfort and disruptions that pervade the lives of patients today – ultimately allowing more patients to live healthier lives to their fullest potential.

    “We are proud to support Dianthus Therapeutics in advancing the discovery and development of next-generation, potent, and highly differentiated antibody complement therapeutics,” said Paula Soteropoulos, Board Director of Dianthus and Strategic Advisor to 5AM Ventures. “With the leadership of the recently appointed President and CEO Marino Garcia, and a talented team of seasoned biotech executives and entrepreneurs who hold an extensive track record of success, we look forward to seeing Dianthus bring their novel therapies to patients living with severe and rare autoimmune diseases.”

    Dianthus is currently led by an accomplished team of veteran scientists and biotech entrepreneurs, including:

    • Marino Garcia, President and Chief Executive Officer
    • Simrat Randhawa, M.D., Chief Medical Officer
    • Evan Thompson, Ph.D., Chief Operating Officer
    • Edward Carr, Chief Accounting Officer
    • Rivka Gluck, Senior Vice President, Head of Clinical Operations
    • Robert McGarr, Ph.D., Vice President, Program & Alliance Management
    • Kristina Maximenko, Head of Human Resources

     

    Dianthus is also supported by an experienced Board of Directors, including:

    • Lonnie Moulder, Chairman of the Board at Dianthus, Founder and Managing Member of Tellus BioVentures
    • Paula Soteropoulos, Chairman of the Board at Ensoma and former CEO of Akcea Therapeutics
    • Lei Meng, Senior Therapeutics Analyst, Avidity Partners
    • Tomas Kiselak, Managing Member of Fairmount
    • Jonathan Violin, Ph.D., Co-founder and Chief Executive Officer of Viridian Therapeutics
    • Marino Garcia, President and Chief Executive Officer, Dianthus Therapeutics

     

    Jefferies LLC served as financial advisor to Dianthus.

     

    About Dianthus Therapeutics

    Dianthus Therapeutics is a biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. Based in Waltham, Mass. and New York City, Dianthus is comprised of an expert team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics to deliver transformative medicines for patients with severe and rare autoimmune diseases. To learn more, please visit www.dianthustx.com.

     

    Media Contact

    Amanda Sellers, Verge Scientific Communications
    asellers@vergescientific.com

X
Privacy Policy

Dianthus Therapeutics (Dianthus) respects the privacy of visitors to its website and is committed to the protection of their personal information. This privacy statement explains data collection and use practices of Dianthus’s website.

Description of the information Dianthus may collect on this website:

Personally Identifiable Information:

Dianthus collects personally identifiable information (i.e., information from which you can be identified, such as name, address, telephone number or e-mail address) only when it is asked for and/or you voluntarily submit it to us on this website. We may use the information to respond to your requests, improve our level of service and the content of our website; provide you with tips, helpful information, product news and updates; notify you of new Dianthus products and services; and for our own internal purposes.

Non-Personally Identifiable Information:

Dianthus also collects non-personally identifiable information in aggregate form to track data such as the total number of visits to our website, the number of visitors to each page of our website and the domain names of our visitors’ internet service providers. We use this information, which remains in aggregate, non-personally identifiable form, to understand how our visitors use our website so that we may improve our website and the services we offer.

Use of IP Addresses:

An Internet Protocol (IP) address is a set of numbers that is automatically assigned to your computer whenever you log on to your internet service provider or through your organization’s local area network (LAN) or wide area network (WAN). Web servers automatically identify your computer by the IP address assigned to it during your session online.

Dianthus or third-party companies acting on behalf of Dianthus may collect IP addresses for the purposes of systems administration and to audit the use of our website. We do not ordinarily link a user’s IP address to personally identifiable information of that user, which means each user’s session will be logged, but the user remains anonymous to us. However, we may use IP addresses to identify users of our website when we feel it is necessary to enforce compliance with the website’s terms of use, or to protect our service, website or other users.

Cookies:

This website uses a technology called “cookies.” A cookie is a small text file that is placed on your hard disk by a web page server. Cookies help provide additional functionality to the website or help us analyze usage of the website more accurately. For instance, our server may set a cookie that keeps you from having to enter a password more than once during a visit to the website. In all cases in which cookies are used, we will not collect personally identifiable information without your explicit permission. The only personally identifiable information Dianthus collects is the information you voluntarily provide.

You have the ability to accept or decline cookies. Most web browsers automatically accept cookies, but you can usually modify your browser setting to decline cookies, or receive a warning before a cookie is stored, if you prefer. Please refer to your internet browser’s instructions or help screen to learn more about these functions. If you choose to decline cookies, you may not be able to fully experience the interactive features of this website or any other websites that you visit.

Sharing Personally Identifiable Information with Third Parties

Dianthus will not sell or rent personally identifiable information to any third party for any purpose. Sometimes selected third parties are used by Dianthus to provide us with support services in connection with our website and such parties may, from time to time, have access to your information to enable them to provide those services to Dianthus. Please rest assured that all companies providing such support services are required by Dianthus to meet certain standards of data protection and are prohibited from using the information for their own marketing purposes.

Links to Other Websites:

This website may provide links to other Dianthus and third-party websites as a service to our users. The privacy statement described here does not apply to those websites. Please ensure you check the legal and privacy statement posted on each website you link to.

Changes:

We may occasionally update this legal and privacy statement. We encourage you to periodically review this legal and privacy statement to stay informed about how we are helping to protect the personal information we collect. Your continued use of our website constitutes your agreement to the terms and conditions for use of our website, our privacy statement and any updates.

X
Terms of Service

Terms of Service Dianthus:


1. Acceptance of the Terms and Conditions.

Dianthus Therapeutics (“Dianthus,” “we,” “us” or “our”) provides and makes available this website (the “Website”). All use of the Website is subject to the terms and conditions contained in the Terms of Service (the “Agreement”). Please read this Agreement carefully. By accessing, browsing or otherwise using the Website, you acknowledge that you have read, understood, and agree to be bound by this Agreement. If you do not accept the terms and conditions of this Agreement, you shall not, and are not permitted to, access, browse or use the Website.

You understand and agree that we may change this Agreement at any time without prior notice. You may read a current, effective copy of this Agreement at any time by selecting the “Terms of Service” link on the Website. The revised terms and conditions will become effective at the time of posting. Any use of the Website after such date constitutes your acceptance of such revised terms and conditions. If any change to this Agreement is not acceptable to you, your sole remedy is to cease accessing, browsing or otherwise using the Website.

Your access to and use of the Website is also subject to our Privacy Policy, which is hereby incorporated herein by reference.

Nothing on this Website should be construed as an offer to form a binding contract, or as granting any license or transfer of intellectual property. Your use of this Website is at your own risk.

PLEASE READ THIS AGREEMENT CAREFULLY, AS THEY CONTAIN AN AGREEMENT TO ARBITRATE, WHICH REQUIRES THAT YOU AND DIANTHUS ARBITRATE CERTAIN CLAIMS BY BINDING, INDIVIDUAL ARBITRATION INSTEAD OF GOING TO COURT, AND LIMIT CLASS ACTION CLAIMS, UNLESS YOU OPT OUT OF THE AGREEMENT TO ARBITRATE AS DESCRIBED IN THE ARBITRATION SECTION (SEE SECTION 8 OF THESE TERMS).

2. Use of the Website.

Medical Information/Conditions. Any information posted on this Website related to medical conditions and their treatment is general in nature and is intended only for educational and general information purposes. Should you have a medical condition that may require treatment, or if you have any specific medical questions, promptly see your own doctor or other health care provider. Nothing on this Website is intended to act as professional medical advice. If you are a patient in a medical emergency, please seek emergency treatment from a doctor or other health care provider instead of reviewing information on this Website. We do not offer medical diagnosis or treatment from this Website, and none of the information contained on this Website should be construed as providing medical advice or services of any kind. Only your doctor or other health care provider can determine if a particular medical treatment is appropriate for you.

Always seek the advice of your doctor or other qualified health care provider before starting any new treatment or with any question that you may have about a medical condition.

Content. The structure, code and organization of this Website are proprietary to us. This Website contains material, including but not limited to software, text, graphics and images (collectively, the “Content”). We may own the Content or portions of the Content may be made available to us through arrangements that we have with one or more third parties. The Content is protected by United States and foreign intellectual property laws. Unauthorized use of any Content may violate copyright, trademark or other laws. You have no rights in or to any Content, and you will not use, copy or display the Content except as permitted in this Agreement. No other use is permitted without our prior written consent. You must retain all copyright and other proprietary notices contained in the original Content on any copy you make of the Content. You may not sell, transfer, assign, license, sublicense or modify any Content or reproduce, display, publicly perform, make a derivative work of, distribute or otherwise use any Content in any way for any purpose, including without limitation any public or commercial purpose. The use or posting of any Content on any other website or in a networked computer environment for any purpose is prohibited. If you violate any part of this Agreement, your right to access and/or use any Content or the Website shall automatically terminate and you shall immediately destroy any copies you have made of any Content.

Trademarks. The trademarks, service marks, and logos owned by Dianthus that are used and displayed on this Website, including without limitation all such marks and logos referencing Dianthus are registered and unregistered trademarks or service marks of Dianthus. Other company, product and service names located on the Website may be trademarks or service marks owned by third parties (the “Third-Party Trademarks”, and, collectively with the Dianthus Trademarks, the “Trademarks”). Nothing on this Website or in this Agreement should be construed as granting, by implication, estoppel, or otherwise, any license or right to use any Trademark displayed on this Website without the prior written consent of Dianthus specific for each such use. The Trademarks may not be used to disparage Dianthus or the applicable third party, Dianthus’s or the third party’s products or services, or in any manner (using commercially reasonable judgment) that may damage any goodwill in the Trademarks. Use of any Trademarks as part of a link to or from any website is prohibited without Dianthus’s prior written consent. All goodwill generated from the use of any Dianthus Trademark shall inure to Dianthus’s benefit. All rights are reserved by the owners of each Trademark, except as otherwise described in this Agreement.

Certain Prohibitions. You agree not to: (a) take any action that imposes an unreasonable load on the Website’s infrastructure, (b) use any device, software or routine to interfere or attempt to interfere with the proper working of the Website or any activity being conducted on the Website, (c) attempt to decipher, decompile, disassemble or reverse engineer any of the software comprising or making up the Website, (d) delete or alter any material posted on the Website by Dianthus or any other person or entity, (e) frame or link to any of the materials or information available on the Website or (f) distribute any virus, Trojan horse, disabling device, time bomb or other code that may impact the operation of the Website, or use the Website to distribute any of the foregoing.

Third Party Links. The Website may contain links and/or references to third party websites and/or services (the “External Sites”). These links are provided solely as a convenience to you and not as an endorsement by us of the content on such External Sites. The content of such External Sites is developed and provided by others. You should contact the site administrator or Webmaster for those External Sites if you have any concerns regarding such links or any content located on such External Sites. We are not responsible for the content of any External Site and do not make any representation regarding the content or accuracy of any materials on any such External Site. You should take precautions when downloading files from all websites to protect your computer from viruses and other destructive programs. If you decide to access any External Site, you do so at your own risk.

Links to Us. Links to any document published by us on this Website must be made to the home page only, without deleting any frames, or our URL address.

Our Social Media. We may use social media accounts from time to time. If you use any social media to communicate with us, please be aware that the terms and privacy policies of the applicable social media platform will govern those communications with us, in addition to this Agreement. Information that you make available on a social media platform may be made available publicly, so we recommend that you not provide us with any information via any social media that you do not feel comfortable making available publicly. We welcome your mentions, replies, comments, likes, suggestions or shares, but please note that any content that you provide to us via a social media channel may be used by us without restriction and without any obligation of payment to you. We will use reasonable efforts to respond to your comments. We may remove or not approve a comment for any reason or no reason, including if it the comment includes vulgar, defamatory, racist, pornographic, violent or other content. There are certain questions or comments that we will not respond to, including without limitation financial data or data on progress of our clinical trials. If we follow any other person’s account, that is not an endorsement. We reserve all rights in relation to use of social media platforms. We do not offer medical diagnosis or treatment via our social media accounts.

3. Limitation of Liability and Disclaimer of Warranties.

Disclaimer of Warranties. THE WEBSITE AND CONTENT ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS WITHOUT ANY WARRANTIES OF ANY KIND. DIANTHUS, ITS AFFILIATES, THEIR RESPECTIVE OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, SUPPLIERS, OR LICENSORS (COLLECTIVELY, THE “DIANTHUS PARTIES“) MAKE NO WARRANTIES OR REPRESENTATIONS ABOUT THE CONTENT, INCLUDING BUT NOT LIMITED TO ITS ACCURACY, RELIABILITY, COMPLETENESS, TIMELINESS OR RELIABILITY, OR THAT DIANTHUS WILL UPDATE SUCH CONTENT OR KEEP SUCH CONTENT CURRENT OR UP TO DATE. THE DIANTHUS PARTIES SHALL NOT BE SUBJECT TO LIABILITY FOR THE TRUTH, ACCURACY OR COMPLETENESS OF THE CONTENT OR ANY OTHER INFORMATION CONVEYED TO YOU, FOR ERRORS, MISTAKES OR OMISSIONS THEREIN OR FOR ANY DELAYS OR INTERRUPTIONS OF THE DATA OR INFORMATION STREAM FROM WHATEVER CAUSE. YOU AGREE THAT YOU USE THE WEBSITE AND THE CONTENT AT YOUR OWN RISK. THE DIANTHUS PARTIES DO NOT WARRANT THAT THE WEBSITE WILL OPERATE ERROR-FREE OR THAT THE WEBSITE, ITS SERVER, OR THE CONTENT ARE FREE OF COMPUTER VIRUSES OR SIMILAR CONTAMINATION OR DESTRUCTIVE FEATURES. IF YOUR USE OF THE WEBSITE OR THE CONTENT RESULTS IN THE NEED FOR SERVICING OR REPLACING EQUIPMENT OR DATA, NO DIANTHUS PARTY SHALL BE RESPONSIBLE FOR THOSE COSTS. THE DIANTHUS PARTIES DISCLAIM ALL WARRANTIES, INCLUDING, BUT NOT LIMITED TO ANY WARRANTY OF TITLE, MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR PARTICULAR PURPOSE.

Limitation of Liability. IN NO EVENT SHALL ANY DIANTHUS PARTY BE LIABLE FOR ANY INCIDENTAL, CONSEQUENTIAL, MULTIPLE, PUNITIVE, SPECIAL OR OTHER INDIRECT DAMAGES, LOST PROFITS, LOST REVENUES, OR DAMAGES RESULTING FROM LOST DATA OR BUSINESS INTERRUPTION) RESULTING FROM THE USE OR INABILITY TO USE THE WEBSITE OR ANY CONTENT, WHETHER BASED ON WARRANTY, CONTRACT, TORT (INCLUDING NEGLIGENCE), OR ANY OTHER LEGAL THEORY, EVEN IF SUCH DIANTHUS PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THE DIANTHUS PARTIES’ AGGREGATE LIABILITY FOR ALL CLAIMS ARISING FROM THIS AGREEMENT SHALL NOT EXCEED THE GREATER OF (I) $1.00 OR (II) THE AGGREGATE AMOUNT YOU HAVE PAID TO US FOR THIS WEBSITE, IF ANY, IN THE THEN-PRIOR TWELVE (12) MONTH PERIOD.

Certain States. Some states do not allow exclusion of implied warranties or limitation of liability for incidental or consequential damages, so the above limitations or exclusions may not apply to you. IN SUCH STATES, THE LIABILITY OF THE DIANTHUS PARTIES SHALL BE LIMITED TO THE GREATEST EXTENT PERMITTED BY LAW.

4. Indemnification

You agree to defend, indemnify, and hold harmless the Dianthus Parties from and against any claims, actions or demands, including, without limitation, reasonable legal and accounting fees, arising or resulting from your breach of this Agreement or your access to, use of or misuse of any Content or the Website. Dianthus will provide notice to you of any such claim, suit, or proceeding. Dianthus reserves the right to assume the exclusive defense and control of any matter which is subject to indemnification under this section. In such case, you agree to cooperate with any reasonable requests assisting Dianthus’s defense of such matter.

5. Termination

Dianthus reserves the right, in its sole discretion, to restrict, suspend, or terminate this Agreement and your access to all or any part of the Website or the Content at any time and for any reason without prior notice or liability. Dianthus reserves the right to change, suspend, or discontinue all or any part of the Website or the Content at any time without prior notice or liability.

Sections 2 (Use of the Website), 3 (Limitation of Liability and Warranty), 4 (Indemnification), 5 (Termination of Agreement), and 9 (General) shall survive the termination of this Agreement.

6. User Must Comply with Applicable Laws.

We make no claims concerning whether the Content may be downloaded, viewed, or be appropriate for use outside of the United States. If you access the Website or the Content from outside of the United States, you do so at your own risk. Whether inside or outside of the United States, you are solely responsible for ensuring compliance with the laws of your specific jurisdiction. You understand that if you access this website from another country and provide your personal information to us through this website, your personal information may be transmitted to us, and you consent to such transfer.

The United States controls the export of products and information. You expressly agree to comply with such restrictions and not to export or re-export any of the Content to countries or persons prohibited under the export control laws. By downloading any Content, you are expressly agreeing that you are not in a country where such export is prohibited or are a person or entity for which such export is prohibited. You are solely responsible for compliance with the laws of your specific jurisdiction regarding the import, export, or re-export of any Content.

7. U.S. Government Restricted Rights.

The Content is provided with “RESTRICTED RIGHTS.” Use, duplication, or disclosure by the Government is subject to the restrictions contained in 48 CFR 52.227-19 and 48 CFR 252.227-7013 et seq. or its successor. Use of the Website or any Content by the Government constitutes acknowledgement of our proprietary rights in the Website and Content.

8. Arbitration

At the election of you or Dianthus, any dispute, claim or controversy arising out of or relating to this Agreement that is not resolved by mutual agreement may be resolved by binding arbitration to be conducted before J.A.M.S. or its successor. Dianthus shall advance the costs of such binding arbitration, but you agree that should we prevail in the arbitration, Dianthus is entitled to reimbursement of all costs. Unless otherwise agreed by the parties, arbitration will be held in Boston, MA, USA before a single arbitrator mutually agreed upon by the parties, or if the parties cannot mutually agree, a single arbitrator appointed by J.A.M.S., and will be conducted in accordance with the rules and regulations promulgated by J.A.M.S. unless specifically modified in this Agreement. The arbitration must commence within forty-five (45) days after the date on which a written demand for arbitration is filed by either party. The arbitrator will have the power to order the production of documents by each party and any third-party witnesses. In addition, each party may take up to three (3) depositions as of right, and the arbitrator will not have the power to order the answering of interrogatories or the responses to requests for admission or the inspection of premises. In connection with any arbitration, each party must provide to the other, no later than ten (10) business days before the date of the arbitration, the identity of all persons that may testify at the arbitration, a copy of all documents that may be introduced at the arbitration or considered or used by a party’s witness or expert, and a summary of the expert’s opinions and the basis for said opinions. The arbitrator’s decision and award shall be made and delivered within sixty (60) days of the conclusion of the arbitration and within six (6) months of the selection of the arbitrator. The arbitrator will not have the power to award damages in excess of the limitation of liability set forth in this Agreement and may not multiply actual damages or award punitive damages or any other damages that are specifically excluded under the Agreement, and each party hereby irrevocably waives any claim to such damages. The parties covenant and agree that they will participate in the arbitration in good faith. The arbitrator may, in his or her discretion, assess costs and expenses (including the reasonable legal fees and expenses of the prevailing part) against any party to a proceeding. Any party refusing to comply with an order of the arbitrators will be liable for costs and expenses, including attorneys’ fees, incurred by the other party in enforcing the award. Notwithstanding the foregoing, in the case of temporary or preliminary injunctive relief, any party may proceed in court without prior arbitration for the purpose of avoiding immediate and irreparable harm. The provisions of this arbitration section will be enforceable in any court of competent jurisdiction.

Any claims brought by you or us must be brought in that party’s individual capacity, and not as a plaintiff or class member in any purported class or representative proceeding. Neither you nor we will participate in a class action or class-wide arbitration for any claims covered by these Terms. You hereby waive any and all rights to bring any claims related to this Agreement, including without limitation our Privacy Policy, as a plaintiff or class member in any purported class or representative proceeding. You may bring claims only on your own behalf.

The arbitration procedures described above in in this Section 8 is the “Agreement to Arbitrate”.

You may opt out of this Agreement to Arbitrate. If you do so, neither you nor we can require the other to participate in an arbitration proceeding. To opt out, you must notify us in writing within thirty (30) days of the date that you first became subject to this arbitration provision. The opt out notice must state that you do not agree to the Agreement to Arbitrate and must include your name, address, phone number, and a clear statement that you want to opt out of this Agreement to Arbitrate. You must sign the opt out notice for it to be effective. This procedure is the only way you can opt out of the Agreement to Arbitrate. You must use this address to opt out:

Dianthus Therapeutics, ATTN: Arbitration Opt-out, 203 Crescent Street, Building 17, Suite 102B, Waltham, MA 02453

Notwithstanding any provision in this Agreement to the contrary, you and we agree that if we make any change to this Agreement to Arbitrate (other than a change to any notice address or website link provided herein) in the future, that change shall not apply to any claim that was filed in a legal proceeding against us prior to the effective date of the change. Moreover, if we seek to terminate the Arbitration Procedures from this Agreement, such termination shall not be effective until thirty (30) days after the version of this Agreement not containing this Agreement to Arbitrate is posted to our Website, and shall not be effective as to any claim that was filed in a legal proceeding against us prior to the effective date of removal.

9. General

This Agreement constitutes the entire agreement between you and Dianthus and governs your use of the Website, superseding any prior agreements between you and Dianthus with respect to the Website. You also may be subject to additional terms and conditions that may apply when you use affiliate services, third-party content or third-party software. This Agreement shall be governed by the laws of the Commonwealth of Massachusetts without regard to its conflict of law provisions. With respect to any disputes or claims not subject to arbitration, as set forth above, you and Dianthus agree to submit to the personal and exclusive jurisdiction of the state and federal courts located in Boston, Massachusetts, USA. EACH OF THE PARTIES HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION (INCLUDING BUT NOT LIMITED TO ANY CLAIMS, COUNTERCLAIMS, CROSS-CLAIMS, OR THIRD PARTY CLAIMS) ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT. FURTHER, EACH PARTY HERETO CERTIFIES THAT NO REPRESENTATIVE OR AGENT OF EITHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH PARTY WOULD NOT IN THE EVENT OF SUCH LITIGATION, SEEK TO ENFORCE THIS WAIVER OF RIGHT TO JURY TRIAL PROVISION. EACH OF THE PARTIES ACKNOWLEDGES THAT THIS SECTION IS A MATERIAL INDUCEMENT FOR THE OTHER PARTY ENTERING INTO THIS AGREEMENT.

The failure of Dianthus to exercise or enforce any right or provision of this Agreement shall not constitute a waiver of such right or provision. If any provision of this Agreement is found by a court of competent jurisdiction to be invalid, the parties nevertheless agree that the court should endeavor to give effect to the parties’ intentions as reflected in the provision, and the other provisions of this Agreement shall remain in full force and effect. You agree that regardless of any statute or law to the contrary, any claim or cause of action arising out of or related to use of the Website or this Agreement must be filed within one (1) year after such claim or cause of action arose or be forever barred. A printed version of this Agreement and of any notice given in electronic form shall be admissible in judicial or administrative proceedings based upon or relating to this agreement to the same extent and subject to the same conditions as other business documents and records originally generated and maintained in printed form. The section titles in this Agreement are for convenience only and have no legal or contractual effect. Notices to you may be made via either email or regular mail. The Website may also provide notices to you of changes to this Agreement or other matters by displaying notices or links to notices generally on the Website.

If you are a California resident, we are required to inform you that you may reach the Complaint Assistance Unit of the Division of Consumer Services of the California Department of Consumer Affairs via mail at 1625 North Market Blvd., Suite N112, Sacramento, CA 95834 or telephone at (916) 445-1254 or (800) 952-5210. Hearing impaired users can reach the Complaint Assistance Unit at TDD (800) 326-2297 or TDD (916) 322-1700.

Copyright © 2021, Dianthus Therapeutics, All Rights Reserved.
Updated: September 29, 2021